Science AdvancesCancer BiologyPeer-reviewed journal article
MAX inactivation deregulates the MYC network and induces neuroendocrine neoplasia in multiple tissues
Brian W. FreieiD, Ali H. IbrahimiD, Patrick A. CarrolliD, Roderick Terry BronsoniD, Arnaud AugertiD, David P MacPhersoniD, Robert N. EisenmaniD
Abstract
The MYC transcription factor requires MAX for DNA binding and widespread activation of gene expression in both normal and neoplastic cells. Surprisingly, inactivating mutations in MAX are associated with a subset of neuroendocrine cancers including pheochromocytoma, pituitary adenoma and small cell lung cancer. Neither the extent nor the mechanisms of MAX tumor suppression are well understood. Deleting Max across multiple mouse neuroendocrine tissues, we find Max inactivation alone produces pituitary adenomas while Max loss cooperates with Rb1/Trp53 loss to accelerate medullary thyroid C-cell and pituitary adenoma development. In the thyroid tumor cell lines, MAX loss triggers a striking shift in genomic occupancy by other members of the MYC network (MNT, MLX, MondoA) supporting metabolism, survival and proliferation of neoplastic neuroendocrine cells. Our work reveals MAX as a broad suppressor of neuroendocrine tumorigenesis through its ability to maintain a balance of genomic occupancies among the diverse transcription factors in the MYC network. TeaserMAX inactivation deregulates multiple transcription factors to induce neuroendocrine cancers
- organism: mouse
- assay: DNA methylation
- assay: ChIP-seq
- research focus: cancer & tumor microenvironment
- research focus: cell type annotation
- research focus: gene regulatory network inference
- approach: experimental assay
- approach: genetic perturbation / CRISPR
- Citations
- 18
- FWCI
- 7.65
- Field percentile
- top 2%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Conditional c-MYC activation in catecholaminergic cells drives distinct neuroendocrine tumors: neuroblastoma vs somatostatinoma
Tingting Wang, Lingling Liu, … Jun Yang·Cancer ResearchPeer-reviewed·Nov 12, 2024
- MYC pathway reprogramming through a TIP60 coactivator switch in neuroendocrine lineage transition in prostate cancer
Zhen Sun, Jimmy Zhao, … Charles L. Sawyers·bioRxiv·May 8, 2026
- Phosphorylation of MYCN and MAX by PAK family kinases is a novel tumor-suppressor mechanism in neuroblastoma with potential therapeutic implications.
E. J. Rozen, K. Wigglesworth, J. M. Shohet·bioRxiv·Dec 4, 2023
- MYC shapes ER-mitochondria calcium transfer by directly targeting ITPR1: implications for MYC-induced safeguard mechanisms and cancer
Xingjie Ma, Athanasios Tsalikis, … David Bernard·bioRxiv·Aug 28, 2024
- MYCN Amplification and ATRX Mutations are Incompatible in Neuroblastoma
M. Zeineldin, S. Federico, … M. Dyer·bioRxiv·Jul 29, 2018
- Inhibition of OCT4 Binding at the MYCN Locus Induces Neuroblastoma Cell Death Accompanied by Downregulation of Transcripts with High-Open Reading Frame Dominance
K. Nakatani, H. Kogashi, … Y. Suenaga·bioRxiv·Jun 8, 2023